Framycetin
Systematic (IUPAC) name | |
---|---|
(2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl) -6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R) -4-[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl) -4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy -5-(hydroxymethyl)oxolan-2-yl]oxy -3-hydroxycyclohexyl]oxyoxane-3,4-diol | |
Clinical data | |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
Legal status | ? |
Routes | oral, topical |
Identifiers | |
CAS number | 119-04-0 |
ATC code | R01AX08 S01AA07 D09AA01 (dressing) QJ01GB91 |
PubChem | CID 8378 |
DrugBank | DB00452 |
ChemSpider | 8075 |
UNII | 4BOC774388 |
KEGG | D05140 |
ChEBI | CHEBI:7508 |
ChEMBL | CHEMBL184618 |
Chemical data | |
Formula | C23H46N6O13 |
Mol. mass | 614.644 g/mol |
SMILES
| |
| |
(what is this?) (verify) | |
Framycetin is an antibiotic of the aminoglycoside class similar to neomycin. Like neomycin, it has poor systemic absorption. It is used in topical preparations for infections of the skin, nose, ears, and eyes, often in combination with other antibacterial drugs and corticosteroids. It can also be used for gastrointestinal infections.
Framycetin is commonly sold as Soframycin and Sofra-Tulle. Also exists in veterinary products, as Framycetin sulf.
|
|